Peptide and Wellness Clinics

The business model is consistent: an initial consultation, a broad laboratory panel, and a prescription for a compounded preparation or an off-label use of an approved drug, often billed as a membership and increasingly delivered by telehealth. None of that is inherently unlawful, since off-label prescribing is recognised practice and compounding is permitted within limits. What differs is that the products are frequently not approved drugs for anything, and the clinic profits from dispensing what it prescribed.

The regulatory record is specific. In 2023 the FDA placed several peptides widely marketed by these clinics into the category of its compounding bulk substances review reserved for substances raising significant safety concerns, closing the 503A route for them. The agency has also issued warning letters over peptide products promoted with disease claims. For a number of the compounds sold in this setting the entire published record is preclinical.

The useful signals are structural. Whether the compound is an approved drug for any indication anywhere; whether the supporting evidence is human or rodent; whether the outcome sold is measurable at all or is defined by how the patient reports feeling; and whether the prescriber's revenue depends on dispensing. A physician's involvement raises the floor on sterile technique and monitoring, but generates no efficacy evidence.

The characteristic error is mistaking monitoring for evidence of benefit. A rising IGF-1 confirms that a secretagogue is engaging the somatotropic axis and is a reasonable safety parameter; it does not show that the sleep, recovery or body-composition outcome sold to the patient followed from it. Alongside it sits the inference that prescribed by a doctor means approved by a regulator, when what is described may be an unapproved substance dispensed under compounding rules.